Sensex

Nifty

USDINR

GBPINR

EURINR

Tuesday, 03 February 2026 12:00 AM EOD	Asian-Paints2426.20	Hind-Unilever2369.35	ITC316.70	Trent3822.65	Larsen-and-Toubro4037.65	M-and-M3527.90	Reliance-Industr1437.85	Tata-Steel192.95	Titan-Company4066.25	SBI1064.25	Bharat-Electron439.00	Kotak-Mah-Bank415.65	Infosys1654.95	Bajaj-Finance964.75	Sun-PharmaInds1702.80	HDFC-Bank948.40	TCS3223.70	ICICI-Bank1389.60	Power-Grid-Corpn283.25	Maruti-Suzuki14779.60	Axis-Bank1355.55	HCL-Technologies1693.70	NTPC358.55	Bharti-Airtel1997.25	Tech-Mahindra1715.65	Adani-Ports1530.90	UltraTech-Cem12586.60	Bajaj-Finserv2013.05	Interglobe-Aviat4945.55	Eternal279.65
15 mins delay SENSEX 83,739.13 [2,072.67]	25.05 1.04%	13.55 0.58%	1.90 0.60%	103.55 2.78%	115.65 2.95%	64.65 1.87%	47.70 3.43%	4.35 2.31%	110.70 2.80%	35.80 3.48%	-0.10 -0.02%	7.45 1.83%	25.95 1.59%	60.40 6.68%	73.90 4.54%	21.10 2.28%	54.40 1.72%	37.40 2.77%	13.10 4.85%	392.55 2.73%	37.70 2.86%	17.60 1.05%	8.15 2.33%	31.65 1.61%	-8.15 -0.47%	128.00 9.12%	54.55 0.44%	82.85 4.29%	258.05 5.51%	6.95 2.55%

Corporate News

Latest News about business and investments.

NATCO Pharma receives USFDA tentative approval for Erdafitinib tablets

03-Feb-26 19:01Hrs IST

NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa' by Janssen Biotech Inc.

NATCO's Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy.

Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep'25 as per industry sales data.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise